• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Long-term active surveillance may be safe in low-risk prostate cancer

byMonica ParksandDavid Wang
December 20, 2014
in Chronic Disease, Oncology, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a cohort of more than 900 low-risk prostate cancer patients followed for up to 15 years, 2.8% of patients developed metastatic disease and 1.5% died of prostate cancer.

2. The relative likelihood of dying from other causes compared to dying from prostate cancer death in this cohort was 9.2 to 1.

Evidence Rating Level: 2 (Good)

Study Rundown: Prostate cancer is the most common malignancies in men, with a lifetime risk of 1 in 7. Active surveillance (AS) is the process of forgoing initial definitive treatment for delayed definitive intervention when specific signs of disease progression has occurred. AS has previously been demonstrated to be effective in patients with low-risk (Gleason 6) prostate cancer, however, there has been no previous studies reporting the long-term outcomes of patients on AS. The authors of this trial presented the 15-year follow-up results of a prospective patient cohort of 993 low-risk prostate cancer patients on AS. Within this cohort, the overall survival rate was 85%, with only 15 (1.5%) reported deaths from prostate cancer and 13 (1.3%) reported cases of prostate cancer metastasis. Within this cohort, the risk associated with dying from other causes was 9.2 times greater than the risk of dying from prostate cancer. The results of this study demonstrate that AS may be a may be a safe treatment approach in low-risk prostate cancer. Furthermore, the development of new imaging techniques and molecular biomarkers (which were not used in this cohort) may detect occult high grade disease and may further help distinguish the appropriate patients for AS treatment.

Click to read the study in JCO

Relevant Reading: Active surveillance for clinically localized prostate cancer–A systematic review

RELATED REPORTS

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Exercise improves sexual function in men with prostate cancer  

In-Depth [prospective cohort]: In this prospective, single-arm cohort study, the authors enrolled a total of 993 men with low or intermediate-risk (Gleason 6-7) prostate cancer from a single academic center. Major outcomes measured included overall and disease-specific survival, rate of treatment, and PSA failure rate among treated patients. The median age was 67.8 (range: 41-89) years. The median follow-up time from first biopsy was 6.4 years (range 0.2 to 19.8 years). Over 200 patients were followed for more than 10 years and 50 patients were followed for more than 15 years. Overall, 149 patients (15%) died. Within this group, the prostate cancer specific mortality was only 1.5% (15 patients). Another 1.3% (13 patients) developed metastatic disease. The median time to metastasis was 7.3 years (95% CI: 5.81 to 8.76). 27% (267 patients) have received intervention due to disease progression. The percentage of patients that remained on AS at 5, 10, and 15 years were 75.7%, 63.5%, and 55%, respectively. Multivariate Cox proportional hazard regression analysis demonstrated that age >70 (HR: 2.87; 95% CI: 1.88 to 4.38, p<0.001), Gleason score >6 (HR: 1.70; 95% CI: 1.14 to 2.55; p<0.01) were significantly associated with decreased survival.

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

Image: CC/Wiki/Nephron

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: prostate cancer
Previous Post

Cell-loaded scaffold implant may improve cell therapy [PreClinical]

Next Post

Ghrelin-receptor agonists may be beneficial in cancer anorexia-cachexia syndrome

RelatedReports

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Exercise improves sexual function in men with prostate cancer  

May 24, 2025
BRAF V600E mutations linked with increased mortality in thyroid cancer
Oncology

Genome classifiers may aid prostate cancer risk stratification and treatment

January 20, 2025
Next Post
Ghrelin-receptor agonists may be beneficial in cancer anorexia-cachexia syndrome

Ghrelin-receptor agonists may be beneficial in cancer anorexia-cachexia syndrome

Less wound complications with suture skin closure after C-section

Less wound complications with suture skin closure after C-section

Autism associated with air pollution exposure during pregnancy

Autism associated with air pollution exposure during pregnancy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.